Product Review

What is it?

This app is made for people who manage multiple projects in their work and personal life at the same time. It walks users through the process of collecting ideas, processing them into manageable tasks, reviewing priorities, and completing tasks. It is the best app on the market for organizing your life and helping you get things done.

How does it work?

The first time you use OmniFocus, you perform what is called a “mind sweep” and enter everything that is on your mind that may require an eventual action into the Inbox. You enter everything including tasks, ideas, Web sites, daydreams, e-mails, and telephone calls into the Inbox. To make it easy, a variety of tools are provided for entry into the Inbox including an Inbox screen, a New Inbox Item button, a Clippings shortcut, and an e-mail shortcut. OmniFocus also pulls data from Siri and the iPhone calendar app to collect all your tasks into 1 app.

Once all the tasks and ideas that are cluttering up your brain are entered, OmniFocus provides a variety of tools to help you process and organize your life. Tasks can be checked off, grouped into projects, placed On Hold as a delegated task, marked as Waiting if it depends on another action, or placed in a Someday Maybe file. Organization is also aided by Ticklers including start dates, due dates, contexts (eg, home, office) and flags. Finally, folders can be created to organize projects into life roles (eg, work, home, personal) or areas of focus (ie, publishing, medical societies).

When it is time to start working, OmniFocus provides you with a variety of views to easily see what needs to be done. Context view allows you to view tasks based on the tool, person, or place needed to complete the task. Project view allows you to view tasks based on the projects you are currently undertaking. You also can view tasks based on those that are due today or those that you flagged as important. Finally, you can easily create views such as a “today view” that only displays tasks you can complete today.

How can it help me?

This app has been a lifesaver for me. Between my work life, home life, and community life, I am constantly juggling several projects at once. This app allows me to have a busy life and never miss an important deadline because something slipped through the cracks. However, OmniFocus does have a steep learning curve, so I would only use this app if you need to balance many projects in your life; many people can get by with a paper to-do list or an e-mail list. 

Learn more about the Getting Things Done system and OmniFocus by reading “OmniFocus, GTD, and You”.

How can I get it?

OmniFocus can be downloaded for free from the Apple App Store for your iPhone and/or iPad and the product Web site. OmniFocus is not available for Android devices at this time.

If you would like to recommend an app, e-mail our Editorial Office.

What is it?

This app is made for people who manage multiple projects in their work and personal life at the same time. It walks users through the process of collecting ideas, processing them into manageable tasks, reviewing priorities, and completing tasks. It is the best app on the market for organizing your life and helping you get things done.

How does it work?

The first time you use OmniFocus, you perform what is called a “mind sweep” and enter everything that is on your mind that may require an eventual action into the Inbox. You enter everything including tasks, ideas, Web sites, daydreams, e-mails, and telephone calls into the Inbox. To make it easy, a variety of tools are provided for entry into the Inbox including an Inbox screen, a New Inbox Item button, a Clippings shortcut, and an e-mail shortcut. OmniFocus also pulls data from Siri and the iPhone calendar app to collect all your tasks into 1 app.

Once all the tasks and ideas that are cluttering up your brain are entered, OmniFocus provides a variety of tools to help you process and organize your life. Tasks can be checked off, grouped into projects, placed On Hold as a delegated task, marked as Waiting if it depends on another action, or placed in a Someday Maybe file. Organization is also aided by Ticklers including start dates, due dates, contexts (eg, home, office) and flags. Finally, folders can be created to organize projects into life roles (eg, work, home, personal) or areas of focus (ie, publishing, medical societies).

When it is time to start working, OmniFocus provides you with a variety of views to easily see what needs to be done. Context view allows you to view tasks based on the tool, person, or place needed to complete the task. Project view allows you to view tasks based on the projects you are currently undertaking. You also can view tasks based on those that are due today or those that you flagged as important. Finally, you can easily create views such as a “today view” that only displays tasks you can complete today.

How can it help me?

This app has been a lifesaver for me. Between my work life, home life, and community life, I am constantly juggling several projects at once. This app allows me to have a busy life and never miss an important deadline because something slipped through the cracks. However, OmniFocus does have a steep learning curve, so I would only use this app if you need to balance many projects in your life; many people can get by with a paper to-do list or an e-mail list. 

Learn more about the Getting Things Done system and OmniFocus by reading “OmniFocus, GTD, and You”.

How can I get it?

OmniFocus can be downloaded for free from the Apple App Store for your iPhone and/or iPad and the product Web site. OmniFocus is not available for Android devices at this time.

If you would like to recommend an app, e-mail our Editorial Office.

What is it?

This app is made for people who manage multiple projects in their work and personal life at the same time. It walks users through the process of collecting ideas, processing them into manageable tasks, reviewing priorities, and completing tasks. It is the best app on the market for organizing your life and helping you get things done.

How does it work?

The first time you use OmniFocus, you perform what is called a “mind sweep” and enter everything that is on your mind that may require an eventual action into the Inbox. You enter everything including tasks, ideas, Web sites, daydreams, e-mails, and telephone calls into the Inbox. To make it easy, a variety of tools are provided for entry into the Inbox including an Inbox screen, a New Inbox Item button, a Clippings shortcut, and an e-mail shortcut. OmniFocus also pulls data from Siri and the iPhone calendar app to collect all your tasks into 1 app.

Once all the tasks and ideas that are cluttering up your brain are entered, OmniFocus provides a variety of tools to help you process and organize your life. Tasks can be checked off, grouped into projects, placed On Hold as a delegated task, marked as Waiting if it depends on another action, or placed in a Someday Maybe file. Organization is also aided by Ticklers including start dates, due dates, contexts (eg, home, office) and flags. Finally, folders can be created to organize projects into life roles (eg, work, home, personal) or areas of focus (ie, publishing, medical societies).

When it is time to start working, OmniFocus provides you with a variety of views to easily see what needs to be done. Context view allows you to view tasks based on the tool, person, or place needed to complete the task. Project view allows you to view tasks based on the projects you are currently undertaking. You also can view tasks based on those that are due today or those that you flagged as important. Finally, you can easily create views such as a “today view” that only displays tasks you can complete today.

How can it help me?

This app has been a lifesaver for me. Between my work life, home life, and community life, I am constantly juggling several projects at once. This app allows me to have a busy life and never miss an important deadline because something slipped through the cracks. However, OmniFocus does have a steep learning curve, so I would only use this app if you need to balance many projects in your life; many people can get by with a paper to-do list or an e-mail list. 

Learn more about the Getting Things Done system and OmniFocus by reading “OmniFocus, GTD, and You”.

How can I get it?

OmniFocus can be downloaded for free from the Apple App Store for your iPhone and/or iPad and the product Web site. OmniFocus is not available for Android devices at this time.

If you would like to recommend an app, e-mail our Editorial Office.

Cimzia

UCB, Inc, obtains US Food and Drug Administration approval of Cimzia (certolizumab pegol), a tumor necrosis factor blocker for the treatment of active psoriatic arthritis in adults. Cimzia also is indicated in adults for the treatment of moderate to severe rheumatoid arthritis and to reduce signs and symptoms of moderately to severely active Crohn disease. For more information, visit www.cimzia.com.

La Roche-Posay Antiaging Products

La Roche-Posay Laboratoire Dermatologique releases 3 antiaging products: Mela-D Deep Cleansing Brightening Foaming Cream, Redermic [R] Eyes, and Substiane [+] Serum. The Mela-D product is a deep-cleansing and brightening formula with lipohy-droxy acid that combats dark spots and gives the skin a clean and smooth appearance. Redermic [R] Eyes combines 0.01% pure retinol with a retinol booster complex and caffeine to reduce crow’s-feet and dark circles to rejuvenate the eye area. Substiane [+] Serum increases the volume and elasticity of the skin. All products are physician dispensed or available in select drugstores and online. For more information, visit www.laroche-posay.us.

Otrexup

Antares Pharma Inc obtains US Food and Drug Administration approval of Otrexup (methotrexate), a folate analog metabolic inhibitor for the treatment of severe, recalcitrant, disabling psoriasis in adults who have not responded to other therapies. Otrexup is self-administered subcutaneously once weekly via an easy-to-use, single-dose, disposable autoinjector, which utilizes Vibex Medi-Jet technology. Otrexup also is indicated for adults with severe active rheumatoid arthritis and for children with active polyarticular juvenile idiopathic arthritis. For more information, visit www.otrexup.com.

Valeant Partners With National Coalition Against Domestic

Violence Valeant Pharmaceuticals International, Inc, announces a partnership with the National Coalition Against Domestic Violence (NCADV) to help improve the lives of women. Valeant pledges to donate a portion of sales from Medicis and Obagi products to support the initiatives of the NCADV. For more information, visit enddomesticviolence.valeant.com.

If you would like your product included in Product News, please e-mail a press release to Melissa Steiger at msteiger@frontlinemedcom.com.

Cimzia

UCB, Inc, obtains US Food and Drug Administration approval of Cimzia (certolizumab pegol), a tumor necrosis factor blocker for the treatment of active psoriatic arthritis in adults. Cimzia also is indicated in adults for the treatment of moderate to severe rheumatoid arthritis and to reduce signs and symptoms of moderately to severely active Crohn disease. For more information, visit www.cimzia.com.

La Roche-Posay Antiaging Products

La Roche-Posay Laboratoire Dermatologique releases 3 antiaging products: Mela-D Deep Cleansing Brightening Foaming Cream, Redermic [R] Eyes, and Substiane [+] Serum. The Mela-D product is a deep-cleansing and brightening formula with lipohy-droxy acid that combats dark spots and gives the skin a clean and smooth appearance. Redermic [R] Eyes combines 0.01% pure retinol with a retinol booster complex and caffeine to reduce crow’s-feet and dark circles to rejuvenate the eye area. Substiane [+] Serum increases the volume and elasticity of the skin. All products are physician dispensed or available in select drugstores and online. For more information, visit www.laroche-posay.us.

Otrexup

Antares Pharma Inc obtains US Food and Drug Administration approval of Otrexup (methotrexate), a folate analog metabolic inhibitor for the treatment of severe, recalcitrant, disabling psoriasis in adults who have not responded to other therapies. Otrexup is self-administered subcutaneously once weekly via an easy-to-use, single-dose, disposable autoinjector, which utilizes Vibex Medi-Jet technology. Otrexup also is indicated for adults with severe active rheumatoid arthritis and for children with active polyarticular juvenile idiopathic arthritis. For more information, visit www.otrexup.com.

Valeant Partners With National Coalition Against Domestic

Violence Valeant Pharmaceuticals International, Inc, announces a partnership with the National Coalition Against Domestic Violence (NCADV) to help improve the lives of women. Valeant pledges to donate a portion of sales from Medicis and Obagi products to support the initiatives of the NCADV. For more information, visit enddomesticviolence.valeant.com.

If you would like your product included in Product News, please e-mail a press release to Melissa Steiger at msteiger@frontlinemedcom.com.

Cimzia

UCB, Inc, obtains US Food and Drug Administration approval of Cimzia (certolizumab pegol), a tumor necrosis factor blocker for the treatment of active psoriatic arthritis in adults. Cimzia also is indicated in adults for the treatment of moderate to severe rheumatoid arthritis and to reduce signs and symptoms of moderately to severely active Crohn disease. For more information, visit www.cimzia.com.

La Roche-Posay Antiaging Products

La Roche-Posay Laboratoire Dermatologique releases 3 antiaging products: Mela-D Deep Cleansing Brightening Foaming Cream, Redermic [R] Eyes, and Substiane [+] Serum. The Mela-D product is a deep-cleansing and brightening formula with lipohy-droxy acid that combats dark spots and gives the skin a clean and smooth appearance. Redermic [R] Eyes combines 0.01% pure retinol with a retinol booster complex and caffeine to reduce crow’s-feet and dark circles to rejuvenate the eye area. Substiane [+] Serum increases the volume and elasticity of the skin. All products are physician dispensed or available in select drugstores and online. For more information, visit www.laroche-posay.us.

Otrexup

Antares Pharma Inc obtains US Food and Drug Administration approval of Otrexup (methotrexate), a folate analog metabolic inhibitor for the treatment of severe, recalcitrant, disabling psoriasis in adults who have not responded to other therapies. Otrexup is self-administered subcutaneously once weekly via an easy-to-use, single-dose, disposable autoinjector, which utilizes Vibex Medi-Jet technology. Otrexup also is indicated for adults with severe active rheumatoid arthritis and for children with active polyarticular juvenile idiopathic arthritis. For more information, visit www.otrexup.com.

Valeant Partners With National Coalition Against Domestic

Violence Valeant Pharmaceuticals International, Inc, announces a partnership with the National Coalition Against Domestic Violence (NCADV) to help improve the lives of women. Valeant pledges to donate a portion of sales from Medicis and Obagi products to support the initiatives of the NCADV. For more information, visit enddomesticviolence.valeant.com.

If you would like your product included in Product News, please e-mail a press release to Melissa Steiger at msteiger@frontlinemedcom.com.

What is it?

PubMed for Handhelds (PubMed4Hh) is an app created by the National Library of Medicine to facilitate evidence-based medical practice at the point of care using mobile devices. It allows physicians to access journal abstracts and “The Bottom Line” (TBL) summaries, and to select full-text articles.

How does it work?

On opening the app, the user is presented with a directory of 6 mobile-friendly interfaces for searching PubMed: PICO, Consensus Abstracts, askMEDLINE, BabelMeSH, CQs (Clinical Queries), and Archive.

PICO guides the user through the process of creating a well-formulated clinical query based on entering a patient/problem (medical condition), intervention (therapy, diagnostic test), comparison, outcome, and publication type (clinical trial, meta-analysis, randomized controlled trial, systematic reviews, practice guideline).

Consensus Abstracts displays search results with multiple selected abstracts or TBL’s on the same page. Searches are initiated using the PICO or askMEDLINE format.

askMEDLINE allows the provider to search using natural language, such as “What are therapeutic options for melanoma?” Results can be narrowed by publication type.

BabelMeSH allows MEDLINE searches in 12 languages in addition to English: Arabic, Chinese, Dutch, French, German, Italian, Japanese, Korean, Portuguese, Russian, Spanish, and Swedish. It also allows searches using PubMed syntax. For example, “Melanoma[majr]” will restrict citations to those in which melanoma is the major topic or focus of the article and “Melanoma 2002:2004[dp]” will restrict citations to those published between 2002 and 2004.

CQs (Clinical Queries) provides a user interface to add filters for limiting PubMed searches to systematic reviews or a specific emphasis (therapy, diagnosis, etiology, prognosis, clinical prediction guides). Users also can indicate if they prefer a specific (narrow) or sensitive (broad) search. PubMed syntax can be used in this interface.

Archive stores saved search results.

How can it help me?

Because the National Library of Medicine created it, PubMed4Hh is the most reputable and authoritative PubMed search tool for mobile devices. It is excellent for providing access to MEDLINE’s extensive library of journal abstracts and TBL summaries. That being said, the current user interface is confusing and it takes time to become familiar with it. I also do not enjoy being required to learn new syntax to optimize search results. Finally, most of the resources have bugs related to screen space and will not fully display on smartphones, requiring the larger screen of a tablet.

I recommend familiarizing yourself with the application by playing with it in clinic for a couple days, and one of the resources will become your favorite platform for point-of-care retrieval of evidence-based data. I mainly use the Consensus Abstracts resource to view multiple TBLs on the same page. I also have used the syntax “[majr]” to focus searches to my topic and “[dp]” to limit searches to specific dates of publication. Although I do not suggest learning a complete syntax, providers who are interested in expanding their PubMed syntax skills can find a complete tutorial at http://www.ncbi.nlm.nih.gov/books/nbk3827.

How can I get it?

PubMed4Hh can be downloaded for free from the Apple App Store, the Google Play Store, and the product Web site.

What is it?

PubMed for Handhelds (PubMed4Hh) is an app created by the National Library of Medicine to facilitate evidence-based medical practice at the point of care using mobile devices. It allows physicians to access journal abstracts and “The Bottom Line” (TBL) summaries, and to select full-text articles.

How does it work?

On opening the app, the user is presented with a directory of 6 mobile-friendly interfaces for searching PubMed: PICO, Consensus Abstracts, askMEDLINE, BabelMeSH, CQs (Clinical Queries), and Archive.

PICO guides the user through the process of creating a well-formulated clinical query based on entering a patient/problem (medical condition), intervention (therapy, diagnostic test), comparison, outcome, and publication type (clinical trial, meta-analysis, randomized controlled trial, systematic reviews, practice guideline).

Consensus Abstracts displays search results with multiple selected abstracts or TBL’s on the same page. Searches are initiated using the PICO or askMEDLINE format.

askMEDLINE allows the provider to search using natural language, such as “What are therapeutic options for melanoma?” Results can be narrowed by publication type.

BabelMeSH allows MEDLINE searches in 12 languages in addition to English: Arabic, Chinese, Dutch, French, German, Italian, Japanese, Korean, Portuguese, Russian, Spanish, and Swedish. It also allows searches using PubMed syntax. For example, “Melanoma[majr]” will restrict citations to those in which melanoma is the major topic or focus of the article and “Melanoma 2002:2004[dp]” will restrict citations to those published between 2002 and 2004.

CQs (Clinical Queries) provides a user interface to add filters for limiting PubMed searches to systematic reviews or a specific emphasis (therapy, diagnosis, etiology, prognosis, clinical prediction guides). Users also can indicate if they prefer a specific (narrow) or sensitive (broad) search. PubMed syntax can be used in this interface.

Archive stores saved search results.

How can it help me?

Because the National Library of Medicine created it, PubMed4Hh is the most reputable and authoritative PubMed search tool for mobile devices. It is excellent for providing access to MEDLINE’s extensive library of journal abstracts and TBL summaries. That being said, the current user interface is confusing and it takes time to become familiar with it. I also do not enjoy being required to learn new syntax to optimize search results. Finally, most of the resources have bugs related to screen space and will not fully display on smartphones, requiring the larger screen of a tablet.

I recommend familiarizing yourself with the application by playing with it in clinic for a couple days, and one of the resources will become your favorite platform for point-of-care retrieval of evidence-based data. I mainly use the Consensus Abstracts resource to view multiple TBLs on the same page. I also have used the syntax “[majr]” to focus searches to my topic and “[dp]” to limit searches to specific dates of publication. Although I do not suggest learning a complete syntax, providers who are interested in expanding their PubMed syntax skills can find a complete tutorial at http://www.ncbi.nlm.nih.gov/books/nbk3827.

How can I get it?

PubMed4Hh can be downloaded for free from the Apple App Store, the Google Play Store, and the product Web site.

What is it?

PubMed for Handhelds (PubMed4Hh) is an app created by the National Library of Medicine to facilitate evidence-based medical practice at the point of care using mobile devices. It allows physicians to access journal abstracts and “The Bottom Line” (TBL) summaries, and to select full-text articles.

How does it work?

On opening the app, the user is presented with a directory of 6 mobile-friendly interfaces for searching PubMed: PICO, Consensus Abstracts, askMEDLINE, BabelMeSH, CQs (Clinical Queries), and Archive.

PICO guides the user through the process of creating a well-formulated clinical query based on entering a patient/problem (medical condition), intervention (therapy, diagnostic test), comparison, outcome, and publication type (clinical trial, meta-analysis, randomized controlled trial, systematic reviews, practice guideline).

Consensus Abstracts displays search results with multiple selected abstracts or TBL’s on the same page. Searches are initiated using the PICO or askMEDLINE format.

askMEDLINE allows the provider to search using natural language, such as “What are therapeutic options for melanoma?” Results can be narrowed by publication type.

BabelMeSH allows MEDLINE searches in 12 languages in addition to English: Arabic, Chinese, Dutch, French, German, Italian, Japanese, Korean, Portuguese, Russian, Spanish, and Swedish. It also allows searches using PubMed syntax. For example, “Melanoma[majr]” will restrict citations to those in which melanoma is the major topic or focus of the article and “Melanoma 2002:2004[dp]” will restrict citations to those published between 2002 and 2004.

CQs (Clinical Queries) provides a user interface to add filters for limiting PubMed searches to systematic reviews or a specific emphasis (therapy, diagnosis, etiology, prognosis, clinical prediction guides). Users also can indicate if they prefer a specific (narrow) or sensitive (broad) search. PubMed syntax can be used in this interface.

Archive stores saved search results.

How can it help me?

Because the National Library of Medicine created it, PubMed4Hh is the most reputable and authoritative PubMed search tool for mobile devices. It is excellent for providing access to MEDLINE’s extensive library of journal abstracts and TBL summaries. That being said, the current user interface is confusing and it takes time to become familiar with it. I also do not enjoy being required to learn new syntax to optimize search results. Finally, most of the resources have bugs related to screen space and will not fully display on smartphones, requiring the larger screen of a tablet.

I recommend familiarizing yourself with the application by playing with it in clinic for a couple days, and one of the resources will become your favorite platform for point-of-care retrieval of evidence-based data. I mainly use the Consensus Abstracts resource to view multiple TBLs on the same page. I also have used the syntax “[majr]” to focus searches to my topic and “[dp]” to limit searches to specific dates of publication. Although I do not suggest learning a complete syntax, providers who are interested in expanding their PubMed syntax skills can find a complete tutorial at http://www.ncbi.nlm.nih.gov/books/nbk3827.

How can I get it?

PubMed4Hh can be downloaded for free from the Apple App Store, the Google Play Store, and the product Web site.

What is it?

The Mohs Appropriate Use Criteria (AUC) app is a decision support tool based on the Mohs micrographic surgery AUC published in 2012.¹ The app helps to determine if Mohs surgery is appropriate for your patients at the point of care.

How does it work?

The app walks you through a short series of selections based on tumor and patient characteristics (ie, cancer type, location, recurrent or primary, histologic features, tumor size, if the patient has immunocompromise or a genetic syndrome) and returns a rating on the appropriateness of Mohs surgery using a scale of 1 to 9. The rating indicates if Mohs surgery is appropriate; not appropriate; or uncertain, meaning that there is not enough published evidence to support if Mohs surgery is appropriate. The whole process takes seconds to complete.

How can it help me?

Compared to the 20-page Mohs surgery AUC publication,¹ this application is extremely easy to use at the point of care. It frees me from having to memorize the Mohs AUC or having to wade through an extensive report when I only want to know if Mohs surgery is appropriate. It also will be useful in educating patients who believe every skin cancer requires Mohs surgery.

How can I get it?

Because Mohs AUC is free, every dermatologist should use this mobile app. It can be downloaded from the Apple App Store. It is not available for Android devices at this time.

What is it?

The Mohs Appropriate Use Criteria (AUC) app is a decision support tool based on the Mohs micrographic surgery AUC published in 2012.¹ The app helps to determine if Mohs surgery is appropriate for your patients at the point of care.

How does it work?

The app walks you through a short series of selections based on tumor and patient characteristics (ie, cancer type, location, recurrent or primary, histologic features, tumor size, if the patient has immunocompromise or a genetic syndrome) and returns a rating on the appropriateness of Mohs surgery using a scale of 1 to 9. The rating indicates if Mohs surgery is appropriate; not appropriate; or uncertain, meaning that there is not enough published evidence to support if Mohs surgery is appropriate. The whole process takes seconds to complete.

How can it help me?

Compared to the 20-page Mohs surgery AUC publication,¹ this application is extremely easy to use at the point of care. It frees me from having to memorize the Mohs AUC or having to wade through an extensive report when I only want to know if Mohs surgery is appropriate. It also will be useful in educating patients who believe every skin cancer requires Mohs surgery.

How can I get it?

Because Mohs AUC is free, every dermatologist should use this mobile app. It can be downloaded from the Apple App Store. It is not available for Android devices at this time.

What is it?

The Mohs Appropriate Use Criteria (AUC) app is a decision support tool based on the Mohs micrographic surgery AUC published in 2012.¹ The app helps to determine if Mohs surgery is appropriate for your patients at the point of care.

How does it work?

The app walks you through a short series of selections based on tumor and patient characteristics (ie, cancer type, location, recurrent or primary, histologic features, tumor size, if the patient has immunocompromise or a genetic syndrome) and returns a rating on the appropriateness of Mohs surgery using a scale of 1 to 9. The rating indicates if Mohs surgery is appropriate; not appropriate; or uncertain, meaning that there is not enough published evidence to support if Mohs surgery is appropriate. The whole process takes seconds to complete.

How can it help me?

Compared to the 20-page Mohs surgery AUC publication,¹ this application is extremely easy to use at the point of care. It frees me from having to memorize the Mohs AUC or having to wade through an extensive report when I only want to know if Mohs surgery is appropriate. It also will be useful in educating patients who believe every skin cancer requires Mohs surgery.

How can I get it?

Because Mohs AUC is free, every dermatologist should use this mobile app. It can be downloaded from the Apple App Store. It is not available for Android devices at this time.

Botox Cosmetic

Allergan, Inc, obtains US Food and Drug Administration approval of Botox Cosmetic (onabotulinumtoxinA) for temporary improvement of moderate to severe lateral canthal lines (crow’s-feet) in adults. It blocks nerve impulses and reduces muscle movements around the eyes. This indication will allow physicians to treat both crow’s-feet and frown lines (approved in 2002 for this latter indication) with little downtime for patients. For more information, visit www.allergan.com.

Fabior Foam 0.1%

Stiefel, a GSK company, receives US Food and Drug Administration approval of Fabior (tazarotene) Foam 0.1% for the treatment of acne vulgaris in patients 12 years and older. Fabior Foam is applied once daily before bedtime. For more information, visit www.fabiorfoam.com.

NIA24 Intensive Retinol Repair

Niadyne, Inc, introduces NIA24 Intensive Retinol Repair for photodamage. It targets the major signs of UV damage including wrinkles, hyperpigmentation, lack of firmness, and uneven texture and tone. Formulated with ProNiacin and retinol, NIA24 Intensive Retinol Repair strengthens the skin barrier and increases collagen. It is an alternative for patients who cannot tolerate retinoic acid or traditional retinol treatments. A prescription is not required, and it can be applied daily. For more information, visit www.NIA24.com.

Stelara

Janssen Biotech Inc obtains US Food and Drug Administration approval of Stelara (ustekinumab) to treat patients with active psoriatic arthritis, alone or in combination with methotrexate. Stelara targets the cytokines IL-12 and IL-23 to control joint pain, swelling, and stiffness associated with psoriatic arthritis, in addition to psoriasis plaque thickness, scaling, and redness. Stelara is administered every 12 weeks after 2 starter doses for the treatment of psoriatic arthritis. For more information, visit www.stelarainfo.com.

XTRAC Velocity 7

PhotoMedex Inc introduces XTRAC Velocity 7 with an advanced user interface for psoriasis and vitiligo. Using UVB light, the XTRAC excimer laser treats areas of the skin affected by psoriasis or vitiligo without harming the surrounding tissue. XTRAC Velocity 7 offers increased efficiency, with the rate of output increasing the speed for delivery of treatment. Treatment guidelines and suggestions based on body area are provided using the touch screen. It can be used on hard-to-reach areas such as the elbows, knees, and scalp. Before and after photographs can be stored to show progression of resolution, enhancing patient compliance. The manufacturer also offers a patient advocacy program for patients to call and obtain answers to product and insurance questions from a live operator; patients also can book appointments with a participating physician faster using the XTRAC TeleCare Center. For more information, visit www.xtracnow.com

Botox Cosmetic

Allergan, Inc, obtains US Food and Drug Administration approval of Botox Cosmetic (onabotulinumtoxinA) for temporary improvement of moderate to severe lateral canthal lines (crow’s-feet) in adults. It blocks nerve impulses and reduces muscle movements around the eyes. This indication will allow physicians to treat both crow’s-feet and frown lines (approved in 2002 for this latter indication) with little downtime for patients. For more information, visit www.allergan.com.

Fabior Foam 0.1%

Stiefel, a GSK company, receives US Food and Drug Administration approval of Fabior (tazarotene) Foam 0.1% for the treatment of acne vulgaris in patients 12 years and older. Fabior Foam is applied once daily before bedtime. For more information, visit www.fabiorfoam.com.

NIA24 Intensive Retinol Repair

Niadyne, Inc, introduces NIA24 Intensive Retinol Repair for photodamage. It targets the major signs of UV damage including wrinkles, hyperpigmentation, lack of firmness, and uneven texture and tone. Formulated with ProNiacin and retinol, NIA24 Intensive Retinol Repair strengthens the skin barrier and increases collagen. It is an alternative for patients who cannot tolerate retinoic acid or traditional retinol treatments. A prescription is not required, and it can be applied daily. For more information, visit www.NIA24.com.

Stelara

Janssen Biotech Inc obtains US Food and Drug Administration approval of Stelara (ustekinumab) to treat patients with active psoriatic arthritis, alone or in combination with methotrexate. Stelara targets the cytokines IL-12 and IL-23 to control joint pain, swelling, and stiffness associated with psoriatic arthritis, in addition to psoriasis plaque thickness, scaling, and redness. Stelara is administered every 12 weeks after 2 starter doses for the treatment of psoriatic arthritis. For more information, visit www.stelarainfo.com.

XTRAC Velocity 7

PhotoMedex Inc introduces XTRAC Velocity 7 with an advanced user interface for psoriasis and vitiligo. Using UVB light, the XTRAC excimer laser treats areas of the skin affected by psoriasis or vitiligo without harming the surrounding tissue. XTRAC Velocity 7 offers increased efficiency, with the rate of output increasing the speed for delivery of treatment. Treatment guidelines and suggestions based on body area are provided using the touch screen. It can be used on hard-to-reach areas such as the elbows, knees, and scalp. Before and after photographs can be stored to show progression of resolution, enhancing patient compliance. The manufacturer also offers a patient advocacy program for patients to call and obtain answers to product and insurance questions from a live operator; patients also can book appointments with a participating physician faster using the XTRAC TeleCare Center. For more information, visit www.xtracnow.com

Botox Cosmetic

Allergan, Inc, obtains US Food and Drug Administration approval of Botox Cosmetic (onabotulinumtoxinA) for temporary improvement of moderate to severe lateral canthal lines (crow’s-feet) in adults. It blocks nerve impulses and reduces muscle movements around the eyes. This indication will allow physicians to treat both crow’s-feet and frown lines (approved in 2002 for this latter indication) with little downtime for patients. For more information, visit www.allergan.com.

Fabior Foam 0.1%

Stiefel, a GSK company, receives US Food and Drug Administration approval of Fabior (tazarotene) Foam 0.1% for the treatment of acne vulgaris in patients 12 years and older. Fabior Foam is applied once daily before bedtime. For more information, visit www.fabiorfoam.com.

NIA24 Intensive Retinol Repair

Niadyne, Inc, introduces NIA24 Intensive Retinol Repair for photodamage. It targets the major signs of UV damage including wrinkles, hyperpigmentation, lack of firmness, and uneven texture and tone. Formulated with ProNiacin and retinol, NIA24 Intensive Retinol Repair strengthens the skin barrier and increases collagen. It is an alternative for patients who cannot tolerate retinoic acid or traditional retinol treatments. A prescription is not required, and it can be applied daily. For more information, visit www.NIA24.com.

Stelara

Janssen Biotech Inc obtains US Food and Drug Administration approval of Stelara (ustekinumab) to treat patients with active psoriatic arthritis, alone or in combination with methotrexate. Stelara targets the cytokines IL-12 and IL-23 to control joint pain, swelling, and stiffness associated with psoriatic arthritis, in addition to psoriasis plaque thickness, scaling, and redness. Stelara is administered every 12 weeks after 2 starter doses for the treatment of psoriatic arthritis. For more information, visit www.stelarainfo.com.

XTRAC Velocity 7

PhotoMedex Inc introduces XTRAC Velocity 7 with an advanced user interface for psoriasis and vitiligo. Using UVB light, the XTRAC excimer laser treats areas of the skin affected by psoriasis or vitiligo without harming the surrounding tissue. XTRAC Velocity 7 offers increased efficiency, with the rate of output increasing the speed for delivery of treatment. Treatment guidelines and suggestions based on body area are provided using the touch screen. It can be used on hard-to-reach areas such as the elbows, knees, and scalp. Before and after photographs can be stored to show progression of resolution, enhancing patient compliance. The manufacturer also offers a patient advocacy program for patients to call and obtain answers to product and insurance questions from a live operator; patients also can book appointments with a participating physician faster using the XTRAC TeleCare Center. For more information, visit www.xtracnow.com

What is it?

Rather than memorizing dozens of Web site log-ins and passwords or storing them in a nonsecure method such as a sheet of paper, 1Password stores everything behind 1 master password. The application also allows you to store credit card numbers, secure notes, bank account numbers, and other personal information as an encrypted database. All of the information is synchronized across all of your mobile devices and computers.

How does it work?

To enter 1Password you must first enter a master password, which acts as a gatekeeper to all of the encrypted data you have stored within the application and is separate from the unlock code used to access your mobile device. Therefore, your data is secured behind 2 layers of encryption.

The user interface is intuitive and consists of 3 panes. The pane on the far left includes a tab for a nice Web browser created by 1Password, a settings tab, and 3 folders to help organize your data. The middle pane allows access to your data by category. Categories include Web site log-ins, secure notes, credit card data, identities, and a password generator. There also is an option to add other categories such as bank accounts, membership cards, driver’s license information, and others. The far right pane displays data for the selected record.

Data from selected records can be used in 3 ways. Tapping on individual pieces of data, such as a password, brings up a bubble with the options to copy the password to your clipboard or reveal the password so you can write it down. Tapping on the Web site opens a Web browser, opens the selected Web site, inserts your username and password, and logs into the Web site for you, all in 1 tap. The third way to use the stored data is through your regular Web browser and what is called a URL scheme. When arriving to a password-protected Web site in your normal Web browser (eg, Chrome, Safari), typing the letters op (for One Password) in front of the Web site will open it in 1Password and log into the Web site for you in 1 tap. All of this automation and secure access to your data make 1Password a big time-saver.

How can it help me?

I no longer memorize passwords, keep them on a sheet of paper in my wallet, or store them on my computer desktop. Instead, I have memorized 1 complex password that gives me access to all my confidential data in 1Password, which has uncluttered my brain and improved my security practices. Because I no longer need to memorize passwords, I use 1Password’s password generator to create long, complex, alphanumeric passwords in place of my prior combinations of names and numbers of personal significance (ie, birth dates, anniversaries, children’s names). I no longer write confidential information on loose sheets of paper or hide important passwords on my computer desktop. Because all of my information is synchronized between all my mobile devices and computers, passwords are always at hand.

The Web browser in 1Password also is excellent. If I know I am going to enter a password-protected Web site, I immediately use the 1Password Web browser, which makes username and password entry 1 click away. Credit card information also is 1 click away, allowing me to fill out purchasing forms in 1 click. I also make ample use of the URL scheme, typing op in front of any Web site that requires a password. In 1 click 1Password enters my username and password, and then opens the site for me.

How can I get it?

1Password can be downloaded from the Apple App Store, the Google Play Store, or the product Web site.

What is it?

Rather than memorizing dozens of Web site log-ins and passwords or storing them in a nonsecure method such as a sheet of paper, 1Password stores everything behind 1 master password. The application also allows you to store credit card numbers, secure notes, bank account numbers, and other personal information as an encrypted database. All of the information is synchronized across all of your mobile devices and computers.

How does it work?

To enter 1Password you must first enter a master password, which acts as a gatekeeper to all of the encrypted data you have stored within the application and is separate from the unlock code used to access your mobile device. Therefore, your data is secured behind 2 layers of encryption.

The user interface is intuitive and consists of 3 panes. The pane on the far left includes a tab for a nice Web browser created by 1Password, a settings tab, and 3 folders to help organize your data. The middle pane allows access to your data by category. Categories include Web site log-ins, secure notes, credit card data, identities, and a password generator. There also is an option to add other categories such as bank accounts, membership cards, driver’s license information, and others. The far right pane displays data for the selected record.

Data from selected records can be used in 3 ways. Tapping on individual pieces of data, such as a password, brings up a bubble with the options to copy the password to your clipboard or reveal the password so you can write it down. Tapping on the Web site opens a Web browser, opens the selected Web site, inserts your username and password, and logs into the Web site for you, all in 1 tap. The third way to use the stored data is through your regular Web browser and what is called a URL scheme. When arriving to a password-protected Web site in your normal Web browser (eg, Chrome, Safari), typing the letters op (for One Password) in front of the Web site will open it in 1Password and log into the Web site for you in 1 tap. All of this automation and secure access to your data make 1Password a big time-saver.

How can it help me?

I no longer memorize passwords, keep them on a sheet of paper in my wallet, or store them on my computer desktop. Instead, I have memorized 1 complex password that gives me access to all my confidential data in 1Password, which has uncluttered my brain and improved my security practices. Because I no longer need to memorize passwords, I use 1Password’s password generator to create long, complex, alphanumeric passwords in place of my prior combinations of names and numbers of personal significance (ie, birth dates, anniversaries, children’s names). I no longer write confidential information on loose sheets of paper or hide important passwords on my computer desktop. Because all of my information is synchronized between all my mobile devices and computers, passwords are always at hand.

The Web browser in 1Password also is excellent. If I know I am going to enter a password-protected Web site, I immediately use the 1Password Web browser, which makes username and password entry 1 click away. Credit card information also is 1 click away, allowing me to fill out purchasing forms in 1 click. I also make ample use of the URL scheme, typing op in front of any Web site that requires a password. In 1 click 1Password enters my username and password, and then opens the site for me.

How can I get it?

1Password can be downloaded from the Apple App Store, the Google Play Store, or the product Web site.

What is it?

Rather than memorizing dozens of Web site log-ins and passwords or storing them in a nonsecure method such as a sheet of paper, 1Password stores everything behind 1 master password. The application also allows you to store credit card numbers, secure notes, bank account numbers, and other personal information as an encrypted database. All of the information is synchronized across all of your mobile devices and computers.

How does it work?

To enter 1Password you must first enter a master password, which acts as a gatekeeper to all of the encrypted data you have stored within the application and is separate from the unlock code used to access your mobile device. Therefore, your data is secured behind 2 layers of encryption.

The user interface is intuitive and consists of 3 panes. The pane on the far left includes a tab for a nice Web browser created by 1Password, a settings tab, and 3 folders to help organize your data. The middle pane allows access to your data by category. Categories include Web site log-ins, secure notes, credit card data, identities, and a password generator. There also is an option to add other categories such as bank accounts, membership cards, driver’s license information, and others. The far right pane displays data for the selected record.

Data from selected records can be used in 3 ways. Tapping on individual pieces of data, such as a password, brings up a bubble with the options to copy the password to your clipboard or reveal the password so you can write it down. Tapping on the Web site opens a Web browser, opens the selected Web site, inserts your username and password, and logs into the Web site for you, all in 1 tap. The third way to use the stored data is through your regular Web browser and what is called a URL scheme. When arriving to a password-protected Web site in your normal Web browser (eg, Chrome, Safari), typing the letters op (for One Password) in front of the Web site will open it in 1Password and log into the Web site for you in 1 tap. All of this automation and secure access to your data make 1Password a big time-saver.

How can it help me?

I no longer memorize passwords, keep them on a sheet of paper in my wallet, or store them on my computer desktop. Instead, I have memorized 1 complex password that gives me access to all my confidential data in 1Password, which has uncluttered my brain and improved my security practices. Because I no longer need to memorize passwords, I use 1Password’s password generator to create long, complex, alphanumeric passwords in place of my prior combinations of names and numbers of personal significance (ie, birth dates, anniversaries, children’s names). I no longer write confidential information on loose sheets of paper or hide important passwords on my computer desktop. Because all of my information is synchronized between all my mobile devices and computers, passwords are always at hand.

The Web browser in 1Password also is excellent. If I know I am going to enter a password-protected Web site, I immediately use the 1Password Web browser, which makes username and password entry 1 click away. Credit card information also is 1 click away, allowing me to fill out purchasing forms in 1 click. I also make ample use of the URL scheme, typing op in front of any Web site that requires a password. In 1 click 1Password enters my username and password, and then opens the site for me.

How can I get it?

1Password can be downloaded from the Apple App Store, the Google Play Store, or the product Web site.